Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients.
Saved in:
| Title: | Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients. |
|---|---|
| Authors: | Webb MJ; Department of Hematology/Oncology, Mayo Clinic, Rochester, Minnesota, USA., Neth BJ; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.; Department of Neuro-Oncology, Mayo Clinic, Rochester, Minnesota, USA., Webb LM; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA., Van Gompel JJ; Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA.; Department of Otolaryngology, Mayo Clinic, Rochester, Minnesota, USA., Link MJ; Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA.; Department of Otolaryngology, Mayo Clinic, Rochester, Minnesota, USA., Neff BA; Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA.; Department of Otolaryngology, Mayo Clinic, Rochester, Minnesota, USA., Carlson ML; Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA.; Department of Otolaryngology, Mayo Clinic, Rochester, Minnesota, USA., Driscoll CL; Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA.; Department of Otolaryngology, Mayo Clinic, Rochester, Minnesota, USA., Dornhoffer J; Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA., Ruff MW; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.; Department of Neuro-Oncology, Mayo Clinic, Rochester, Minnesota, USA., Anderson KA; Department of Otolaryngology, Mayo Clinic, Rochester, Minnesota, USA., Kizilbash SH; Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Campian JL; Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Uhm JH; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.; Department of Neuro-Oncology, Mayo Clinic, Rochester, Minnesota, USA., Lane JI; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA., Benson JC; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA., Blezek DJ; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA., Mehta PM; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA., Bathla G; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA., Sener UT; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA. |
| Source: | Neuro-oncology advances [Neurooncol Adv] 2023 Sep 22; Vol. 5 (1), pp. vdad123. Date of Electronic Publication: 2023 Sep 22 (Print Publication: 2023). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 101755003 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-2498 (Electronic) Linking ISSN: 26322498 NLM ISO Abbreviation: Neurooncol Adv Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 37841698 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Webb+MJ%22">Webb MJ</searchLink>; Department of Hematology/Oncology, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Neth+BJ%22">Neth BJ</searchLink>; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.; Department of Neuro-Oncology, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Webb+LM%22">Webb LM</searchLink>; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Van+Gompel+JJ%22">Van Gompel JJ</searchLink>; Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA.; Department of Otolaryngology, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Link+MJ%22">Link MJ</searchLink>; Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA.; Department of Otolaryngology, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Neff+BA%22">Neff BA</searchLink>; Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA.; Department of Otolaryngology, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Carlson+ML%22">Carlson ML</searchLink>; Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA.; Department of Otolaryngology, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Driscoll+CL%22">Driscoll CL</searchLink>; Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA.; Department of Otolaryngology, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Dornhoffer+J%22">Dornhoffer J</searchLink>; Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Ruff+MW%22">Ruff MW</searchLink>; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.; Department of Neuro-Oncology, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Anderson+KA%22">Anderson KA</searchLink>; Department of Otolaryngology, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Kizilbash+SH%22">Kizilbash SH</searchLink>; Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Campian+JL%22">Campian JL</searchLink>; Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Uhm+JH%22">Uhm JH</searchLink>; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.; Department of Neuro-Oncology, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Lane+JI%22">Lane JI</searchLink>; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Benson+JC%22">Benson JC</searchLink>; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Blezek+DJ%22">Blezek DJ</searchLink>; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Mehta+PM%22">Mehta PM</searchLink>; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Bathla+G%22">Bathla G</searchLink>; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Sener+UT%22">Sener UT</searchLink>; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101755003%22">Neuro-oncology advances</searchLink> [Neurooncol Adv] 2023 Sep 22; Vol. 5 (1), pp. vdad123. <i>Date of Electronic Publication: </i>2023 Sep 22 (<i>Print Publication: </i>2023). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101755003 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2632-2498 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226322498%22">26322498 </searchLink><i>NLM ISO Abbreviation: </i>Neurooncol Adv <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37841698 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1093/noajnl/vdad123 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: vdad123 Titles: – TitleFull: Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Webb MJ – PersonEntity: Name: NameFull: Neth BJ – PersonEntity: Name: NameFull: Webb LM – PersonEntity: Name: NameFull: Van Gompel JJ – PersonEntity: Name: NameFull: Link MJ – PersonEntity: Name: NameFull: Neff BA – PersonEntity: Name: NameFull: Carlson ML – PersonEntity: Name: NameFull: Driscoll CL – PersonEntity: Name: NameFull: Dornhoffer J – PersonEntity: Name: NameFull: Ruff MW – PersonEntity: Name: NameFull: Anderson KA – PersonEntity: Name: NameFull: Kizilbash SH – PersonEntity: Name: NameFull: Campian JL – PersonEntity: Name: NameFull: Uhm JH – PersonEntity: Name: NameFull: Lane JI – PersonEntity: Name: NameFull: Benson JC – PersonEntity: Name: NameFull: Blezek DJ – PersonEntity: Name: NameFull: Mehta PM – PersonEntity: Name: NameFull: Bathla G – PersonEntity: Name: NameFull: Sener UT IsPartOfRelationships: – BibEntity: Dates: – D: 22 M: 09 Text: 2023 Sep 22 Type: published Y: 2023 Identifiers: – Type: issn-electronic Value: 2632-2498 Numbering: – Type: volume Value: 5 – Type: issue Value: 1 Titles: – TitleFull: Neuro-oncology advances Type: main |
| ResultId | 1 |